The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
Robert Lance Fine
No relevant relationships to disclose
Anthony Paul Gulati
No relevant relationships to disclose
Dawn Tsushima
No relevant relationships to disclose
Kelley B. Mowatt
No relevant relationships to disclose
Anna Oprescu
No relevant relationships to disclose
Jeffrey N. Bruce
No relevant relationships to disclose
John A. Chabot
No relevant relationships to disclose